Explore Emucare Pharma IPO price range, dates, and refund initiation details
About Emucare Pharma
Established in 1981, Emcure Pharmaceuticals Limited stands as a prominent Indian pharmaceutical entity, engaged in the creation, production, and international distribution of a diverse pharmaceutical portfolio, covering key therapeutic categories.
For the MAT period ending in September 2023, the firm has secured the 13th position in terms of domestic sales among its Indian pharmaceutical peers and holds the 4th rank in market share within its operational markets. Notably, it has attained a leading position in the gynecology and HIV antiviral sectors for the same MAT period.
Emucare Pharmaceuticals, headquartered in Pune, has declared an Emucare Pharma IPO price range of Rs 960 to Rs 1008 per share. The subscription window is set to open on July 3, with anchor investor bidding commencing on July 2. The IPO will conclude on July 5, followed by share allotment on July 8, refund initiation on July 9, and the company’s stock market debut slated for July 10.
The Emucare Pharma IPO comprises a fresh issuance worth Rs 800 crore and a sale offer of Rs 1151 crore by the current promoters and shareholders. At the upper end of the price band, the total issue value amounts to Rs 1952 crore. The anticipated Emucare Pharma IPO market capitalization is approximately Rs 18,260 crore. The selling stakeholders in the offer for sale (OFS) include promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta. Additionally, Pushpa Rajnikant Mehta, Bhavana Satish Mehta, Kamini Sunil Mehta, BC Investments IV, Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, and Sonali Sanjay Mehta will part with their shares in the OFS.
The Emucare Pharma IPO also earmarks 1,08,900 equity shares for the company’s employees, who are eligible for a discount on the final offer price. Excluding the employee segment, the remainder constitutes the net issue.
With a robust footprint in India, Europe, and Canada, Emucare Pharma plans to allocate Rs 600 crore from the net proceeds of the fresh issue to debt repayment. The residual funds are designated for general corporate objectives. As of March 2024, the company’s debt stands at Rs 2,091.9 crore.
In FY24, Emucare generated 48.28% of its revenue from the Indian market, with a presence in most major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, and blood-related sectors.
The company witnessed a 6% year-on-year dip in net profit, recording Rs 527.6 crore for FY24, influenced in part by a subdued operating margin. Operational revenue saw an 11.2% increase to Rs 6,658.3 crore, and EBITDA improved by 4.1% to Rs 1,229.7 crore. However, the margin contracted by 120 basis points to 18.5% for the concluded fiscal year (FY24).
Emcure Pharma IPO Dates
Emucare Pharma IPO Opening: July 3, 2024
Emucare Pharma IPO Closing: July 5, 2024
Allotment Date: July 8, 2024
Refund Initiation: July 9, 2024
Share Credit to Demat: July 9, 2024
Listing Date: July 10, 2024
UPI Mandate Confirmation Deadline: 5 PM on July 5, 2024
